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Sir: With increasing focus on the molecular classification of non-small cell lung cancers 
(NSCLC) to guide therapeutic decisions the correct application of appropriate diagnostic tools 
is paramount.   In small biopsy and cytology specimens the majority can be accurately subtyped 
on their morphological appearances or with the use of additional immunohistochemistry (IHC), 
namely thyroid transcription factor-1 (TTF-1) and p63 and/or p40.1 Despite this, there is still a 
small proportion in which sub-classification is not possible therefore the category “not 
otherwise specified” (NSCLC-NOS) remains valid. This can be the result of a ‘null’ IHC 
phenotype but can also occur in specimens where there are poorly differentiated malignant 
cells but insufficient material for subsequent IHC.    
 
Both the Royal College of Pathologists and Scottish Intercollegiate Guideline Network (SIGN) 
guidelines state that NOS rates should be less than 10% of all NSCLC.1,2  Recent publication 
of the ‘LungPath’ project highlighted marked differences between English pathology 
departments in their rate of NSCLC-NOS (3-20%) with variable application of 
immunohistochemistry (20-100%).3 The wide variation in the reported use of 
immunohistochemistry in this study was striking but, whilst informative, the data did not 
clearly address the issue of whether this related to pathologists’ decisions not to perform IHC 
or to the nature of the specimen submitted.  It therefore prompted us to evaluate the proportion 
of NOS cases in our department which were as a result of IHC not being requested, non-
informative IHC or where insufficient material or unsuitable specimens prevented IHC being 
undertaken. 
 
The audit was conducted in a regional centre where IHC is routinely requested on small 
biopsies and cell blocks from cytology specimens only when there is no clear morphological 
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phenotype. This policy has been in place since 2009 and has reduced our NSCLC-NOS rate for 
biopsy and cytology specimens to <10%.4  In the current audit all patients diagnosed with 
primary lung cancer from 1st January 2012 to 31st December 2014 were identified using the 
South East Scotland Cancer Network (SCAN) database.  The reports of cases classified as 
NSCLC-NOS were reviewed to determine specimen type(s), the use of immunohistochemistry 
and reasons for no further testing. As an audit of clinical practice ethical approval was not 
required.  
 
Of the 2292 patients identified 159 were coded as NSCLC-NOS. Following review of the 
reports 38 were excluded due to incorrect data entry leaving 121 cases. The overall rate of 
NSCLC-NOS for the three-year period examined was 5.3% (Table 1).  IHC was performed on 
92/121 cases. In keeping with the Royal College dataset recommendations TTF-1 and p63 
and/or p40 were used in those cases 100% and 97.8% respectively.  In the 29/121 cases where 
IHC was not performed it was solely due to insufficient material being available.   These 
specimens were all cytology samples, the majority being bronchial brushings/washings (18/29) 
or fine needle aspirates of either extra-thoracic lymph nodes or metastases (5/29) (Table 1). In 
all cases there was either insufficient material for a cell block or the prepared block was 
acellular or contained no malignant cells.  No cases were identified where suitable material had 
been available but IHC was not performed.   
 
Whilst this audit demonstrates a low NOS rate for both histological and cytological specimens 
it also provides clear evidence that IHC rates cannot be taken in isolation as a satisfactory 
marker of a pathology department’s performance. Understanding the components of the 
immunohistochemistry “denominator” are therefore essential.  Awareness of factors including 
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specimen type and quality are necessary to reach an accurate conclusion.  Guidelines and any 
proposed College mandatory audits need to reflect and acknowledge likely variation between 
centres depending on individual case mix, especially where there is more extensive use of 
cytology for primary diagnosis. Failure to do so may result in pathologists being pressured to 
over interpret morphological features in cases where no material for IHC is available in order 
to avoid using the term NSCLC-NOS. What the patient requires is the pathologist to give an 
honest opinion on the available material and if further more detailed classification is needed 
then submission of a further specimen may be required. Whilst audits to ensure quality 
improvement across pathology departments are essential, recognition of factors beyond the 
pathologist’s control is also necessary to ensure an accurate picture is established.  Addressing 
these issues through discussion and education of clinical colleagues with regards to the 
changing tissue requirements for full pathological and molecular assessment may go some way 
towards improved sample acquisition and quality.   
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Table 1. Characteristics of biopsies classified as NSCLC-NOS 
 Cases (%) 
Total cases  2292 
 
NSCLC-NOS  121 (5.3) 
      2012 45 (6.0) 
      2013 37 (4.7) 
      2014 39 (5.2) 
 
Immunohistochemistry 92 (76.0) 
      TTF1 92 (100.0) 
      p63/p40 90 (97.8) 
 
Insufficient for IHC 29 (24.0) 
      Brushing/washing 18 (62.1) 
      Needle FNA 5 (17.2) 
      EBUS FNA 4 (13.8) 
      EBUS miniprobe 1 (3.4) 
      Sputum 1 (3.4) 
  
EBUS: endobronchial ultrasound; FNA, fine needle aspirate; TTF1, thyroid transcription factor 
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